These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Ceftaroline Resistance by Clone-Specific Polymorphism in Penicillin-Binding Protein 2a of Methicillin-Resistant Staphylococcus aureus. Lee H; Yoon EJ; Kim D; Kim JW; Lee KJ; Kim HS; Kim YR; Shin JH; Shin JH; Shin KS; Kim YA; Uh Y; Jeong SH Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941637 [TBL] [Abstract][Full Text] [Related]
5. Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients. Roch M; Varela MC; Taglialegna A; Rose WE; Rosato AE Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914961 [TBL] [Abstract][Full Text] [Related]
6. Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. Alm RA; McLaughlin RE; Kos VN; Sader HS; Iaconis JP; Lahiri SD J Antimicrob Chemother; 2014 Aug; 69(8):2065-75. PubMed ID: 24777906 [TBL] [Abstract][Full Text] [Related]
7. Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. Mendes RE; Tsakris A; Sader HS; Jones RN; Biek D; McGhee P; Appelbaum PC; Kosowska-Shick K J Antimicrob Chemother; 2012 Jun; 67(6):1321-4. PubMed ID: 22398650 [TBL] [Abstract][Full Text] [Related]
8. In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program. Biedenbach DJ; Alm RA; Lahiri SD; Reiszner E; Hoban DJ; Sahm DF; Bouchillon SK; Ambler JE Antimicrob Agents Chemother; 2016 Jan; 60(1):343-7. PubMed ID: 26503659 [TBL] [Abstract][Full Text] [Related]
9. Ceftaroline is active against heteroresistant methicillin-resistant Staphylococcus aureus clinical strains despite associated mutational mechanisms and intermediate levels of resistance. Fernandez R; Paz LI; Rosato RR; Rosato AE Antimicrob Agents Chemother; 2014 Oct; 58(10):5736-46. PubMed ID: 25022592 [TBL] [Abstract][Full Text] [Related]
10. Missense mutations in PBP2A Affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998. Kelley WL; Jousselin A; Barras C; Lelong E; Renzoni A Antimicrob Agents Chemother; 2015 Apr; 59(4):1922-30. PubMed ID: 25583724 [TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline. Lahiri SD; McLaughlin RE; Whiteaker JD; Ambler JE; Alm RA J Antimicrob Chemother; 2015 Sep; 70(9):2488-98. PubMed ID: 26045529 [TBL] [Abstract][Full Text] [Related]
12. Genotypic analysis of Italian MRSA strains exhibiting low-level ceftaroline and ceftobiprole resistance. Bongiorno D; Mongelli G; Stefani S; Campanile F Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114852. PubMed ID: 31288948 [TBL] [Abstract][Full Text] [Related]